Viridian Therapeutics, Inc. Common Stock
XNAS:VRDN
33.29
$35.17 - 30.00
$32.00 - 50.00
$32.89
$33.99
$33.89
$33.78
34.29
9.9
970953
1580342.6
85965372.94
Chart
TendieTensor AI Analysis
Company
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Fundamentals
143
-9.560000
8.375160
100
BBG002H242Z5
BBG002H24301
81.67M
95.37M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own VRDN. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.